Pulmatrix Inc. (PULM)
Summary
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates PULM and ENTO on Behalf of Shareholders
NEW YORK, NY / ACCESSWIRE / November 15, 2024 / Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to: Pulmatrix, Inc. (NASDAQ:PULM)'s merger with Cullgen Inc. Upon closing of the proposed transaction, Pulmatrix stockholders are expected to own approximately 3.6% of the combined company. If you are a Pulmatrix shareholder, click here to learn more about your rights and options.
PULM INVESTOR ALERT: Rigrodsky Law, P.A. Is Investigating Pulmatrix, Inc. Merger
WILMINGTON, DE / ACCESSWIRE / November 14, 2024 / Rigrodsky Law, P.A. is investigating Pulmatrix, Inc. ("Pulmatrix") (NASDAQ CM:PULM) regarding possible breaches of fiduciary duties and other violations of law related to Pulmatrix's agreement to merge with Cullgen Inc. To learn more about this investigation and your rights, visit: Click Here
Pulmatrix Inc. Investors
| Name | Quantity | Cost | Value | Profit ($) | Gain (%) |
|---|---|---|---|---|---|
 Christopher C. Powers Farther Finance Advisors, LLC | 7 | $34 | $10.64 | -$23.36 | -68.71% |
Pulmatrix Inc. (PULM) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Pulmatrix Inc. ever had a stock split?
Pulmatrix Inc. Profile
| Biotechnology Industry | Healthcare Sector | Peter Ludlum CEO | NASDAQ (CM) Exchange | 74584P301 CUSIP |
| US Country | 2 Employees | 6 Feb 2019 Last Dividend | 1 Mar 2022 Last Split | 21 Mar 2014 IPO Date |
Overview
Pulmatrix, Inc. is a pioneering clinical stage biotechnology firm rooted in the United States, committed to the discovery and development of innovative inhaled therapies aimed at preventing and treating a wide range of respiratory conditions and other diseases that currently have unmet medical needs. Central to their strategy is the utilization of their proprietary iSPERSE (inhaled small particles easily respirable and emitted) technology. This technology stands out by enabling the effective delivery of both small and large molecule drugs directly to the lungs through inhalation, catering to local or systemic medical applications. Founded in the year 2003 and with its headquarters in Lexington, Massachusetts, Pulmatrix is positioned at the forefront of addressing critical respiratory conditions with groundbreaking therapeutic solutions.
Products and Services
PUR1800: This innovative therapeutic candidate embodies a narrow spectrum kinase inhibitor and has successfully completed Phase 1b clinical trials. It is specifically formulated for patients suffering from stable moderate to severe chronic obstructive pulmonary disease (COPD), offering a promising new avenue for managing this debilitating respiratory condition.
PUR1900: Aimed at addressing the needs of patients with allergic bronchopulmonary aspergillosis (ABPA), particularly those with concurrent asthma and cystic fibrosis, PUR1900 is a testament to Pulmatrix's commitment to tackling complex respiratory diseases. Through its development, the company seeks to provide a significant improvement in the treatment options available for managing the underlying fungal infections that exacerbate these conditions.
PUR3100: As part of Pulmatrix's diverse product portfolio, PUR3100 is an iSPERSE-formulated version of dihydroergotamine, developed for the acute treatment of migraine. By leveraging their inhalation technology, Pulmatrix aims to offer a rapid, effective solution for migraine sufferers, underscoring the versatility of the iSPERSE technology in addressing a variety of health concerns beyond respiratory diseases.
In their quest to bring these innovative treatments to market, Pulmatrix has established strategic partnerships, including a license agreement with RespiVert Ltd., granting them access to a comprehensive portfolio of kinase inhibitor drug candidates. Additionally, a development and commercialization agreement with Cipla Technologies LLC for PUR1900 marks a significant step towards achieving broader distribution and accessibility for their therapies. With these alliances, Pulmatrix is well-equipped to navigate the complex path from research and development to commercial success, ultimately delivering on their promise to address unmet medical needs through groundbreaking inhaled therapies.
